Evaluation of an integrative therapy approach for the comorbidity of psychosis and addiction.
Not Applicable
- Conditions
- F20F25F10-F19SchizophreniaSchizoaffective disordersMental and behavioural disorders due to psychoactive substance use
- Registration Number
- DRKS00000671
- Lead Sponsor
- Klinik für Psychiatrie und Psychotherapie Uniklinik Köln
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
1. schizophrenic patients
2. acceptance
3. majority
Exclusion Criteria
1. no acceptance because of positive symptoms
2. neuopsychiatric disorders
3. no acceptance of the study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - change/reduction of drug consumption<br>- motivation of change the drug consumption<br><br>quesstionaries: criteries of their drugs, motivation of change<br>
- Secondary Outcome Measures
Name Time Method - psychosis symptoms<br>- Number/duration of inpatient treatment<br>- depressive symptoms<br>- General health <br>- Compliance: Stay in the treatment program (drop-out rates) and especially Medikamteneimnmahme <br>- Subjective life satisfaction <br>- Amount of general psychosocial functioning level <br>- Self-efficacy <br>- Self-assessment resources <br>- Treatment satisfaction<br><br><br>questionaries: <br>demographic, diagnosis, psychosis, SKID-II, depression (MADRS), compliance, medication (GAF - Global assessment of functioning), Subjective life satisfaction (FLZ), Social control (F-SozU), Self-efficacy (SWE), resources (RES-K), treatment satisfaction (ZUF-8)
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the integrative therapy for F20/F25 comorbid with F10-F19 disorders in DRKS00000671?
How does the KLIPS-Study compare integrative therapy outcomes to standard-of-care treatments for schizophrenia and addiction comorbidity?
Are there specific biomarkers identified in DRKS00000671 that predict response to integrative therapy in patients with schizoaffective disorders and substance use?
What adverse events were observed in the DRKS00000671 trial for psychosis-addiction comorbidity and how were they managed?
What combination approaches or competitor drugs are being evaluated alongside integrative therapy for mental and behavioural disorders due to psychoactive substance use in the KLIPS-Study?